Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study (2022)
Fonte: Lancet hiv. Unidade: FM
Assuntos: HIV, COVID-19, VACINAS VIRAIS
ABNT
NETTO, Lucas C et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet hiv, v. 9, n. 5, p. E323-E331, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2352-3018(22)00033-9. Acesso em: 29 ago. 2024.APA
Netto, L. C., Ibrahim, K. Y., Picone, C. M., Alves, A. P. P. S., Aniceto, E. V., Santiago, M. R., et al. (2022). Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet hiv, 9( 5), E323-E331. doi:10.1016/S2352-3018(22)00033-9NLM
Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Bonfa ESD de O, Kallas EG, Silva VHIA da. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study [Internet]. Lancet hiv. 2022 ; 9( 5): E323-E331.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1016/S2352-3018(22)00033-9Vancouver
Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Bonfa ESD de O, Kallas EG, Silva VHIA da. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study [Internet]. Lancet hiv. 2022 ; 9( 5): E323-E331.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1016/S2352-3018(22)00033-9